Company Overview of J5 Acquisition Corp.
As of July 14, 2011, J5 Acquisition Corp. was acquired by Acerus Pharmaceuticals Corporation, in a reverse merger transaction. Trimel Pharmaceuticals Corporation focuses on the redevelopment of known pharmaceutical compounds in order to improve their performance and merchantability by employing localized dosing technologies (LDT) that are designed to avoid first pass metabolism. It acquires three LDT platforms, and pursuing the development and application of these technologies to various high value pharmaceutical compounds. The company focuses on the therapeutic areas of allergy, asthma, and endocrinology. Trimel Pharmaceuticals Corporation is headquartered in Mississauga, Canada.
2488 Dunwin Drive
Mississauga, ON L5L 1J9
Key Executives for J5 Acquisition Corp.
J5 Acquisition Corp. does not have any Key Executives recorded.
Similar Private Companies By Industry
|9037136 Canada Inc.||Americas|
|AAA Heidelberg Inc.||Americas|
|Ab Biotech Inc.||Americas|
|ABcann Medicinals Inc.||Americas|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Citizens Budget Commission||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact J5 Acquisition Corp., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.